IN2014CH00391A - - Google Patents
Info
- Publication number
- IN2014CH00391A IN2014CH00391A IN391CH2014A IN2014CH00391A IN 2014CH00391 A IN2014CH00391 A IN 2014CH00391A IN 391CH2014 A IN391CH2014 A IN 391CH2014A IN 2014CH00391 A IN2014CH00391 A IN 2014CH00391A
- Authority
- IN
- India
- Prior art keywords
- cellular immunity
- peptide
- cancer
- composition
- subject
- Prior art date
Links
- 230000007969 cellular immunity Effects 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013020906 | 2013-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CH00391A true IN2014CH00391A (fr) | 2015-04-03 |
Family
ID=50028737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN391CH2014 IN2014CH00391A (fr) | 2013-02-05 | 2014-01-29 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10449144B2 (fr) |
EP (1) | EP2762159A1 (fr) |
JP (1) | JP6512568B2 (fr) |
KR (1) | KR20140100419A (fr) |
CN (1) | CN103961307B (fr) |
CA (1) | CA2841016A1 (fr) |
IN (1) | IN2014CH00391A (fr) |
RU (1) | RU2687144C2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2626238C (fr) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides |
EP3834836A1 (fr) | 2006-04-10 | 2021-06-16 | Memorial Sloan Kettering Cancer Center | Peptides wt-1 immunogènes et leurs utilisations |
EP2802347B1 (fr) | 2012-01-13 | 2019-01-09 | Memorial Sloan Kettering Cancer Center | Peptides wt-1 immunogènes et leurs procédés d'utilisation |
ES2655031T3 (es) * | 2012-07-02 | 2018-02-16 | Sumitomo Dainippon Pharma Co., Ltd. | Preparación transdérmica de péptido antigénico del cáncer |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
CN116789792A (zh) | 2013-01-15 | 2023-09-22 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽和其使用方法 |
JP6512568B2 (ja) | 2013-02-05 | 2019-05-15 | 日東電工株式会社 | 経皮投与用wt1ペプチド癌ワクチン組成物 |
RU2697443C2 (ru) | 2013-02-05 | 2019-08-14 | Нитто Денко Корпорейшн | Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения |
JP6294868B2 (ja) | 2013-03-12 | 2018-03-14 | 大日本住友製薬株式会社 | 液体水性組成物 |
JP6577795B2 (ja) * | 2014-09-03 | 2019-09-18 | 日東電工株式会社 | ビスホスホネート剤を含む細胞性免疫用ワクチン医薬組成物 |
JP2016074654A (ja) * | 2014-10-02 | 2016-05-12 | 日東電工株式会社 | 経皮投与用ワクチン医薬組成物 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
AU4932199A (en) | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
IL127331A0 (en) | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
US20030082194A1 (en) * | 2000-02-22 | 2003-05-01 | Alexander Gaiger | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
US20030232055A1 (en) * | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
RU2192884C2 (ru) * | 2000-11-09 | 2002-11-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Вакцина для стимуляции противоопухолевого иммунитета |
CA2440303C (fr) | 2001-03-22 | 2013-03-19 | Haruo Sugiyama | Peptide modifie wt1 |
US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
CN101113163B (zh) | 2002-06-12 | 2010-10-06 | 株式会社国际癌症免疫研究所 | Hla-a24限制性癌抗原肽 |
DE60329201D1 (de) | 2002-09-20 | 2009-10-22 | Chugai Pharmaceutical Co Ltd | Substituierte wt1-peptide |
US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
KR20130062368A (ko) | 2003-11-05 | 2013-06-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 유래의 hla-dr 결합성 항원 펩티드 |
US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
WO2005089777A1 (fr) | 2004-03-15 | 2005-09-29 | Karaolis David K R | Procede inhibant la proliferation et accroissant l'apoptose de cellules cancereuses |
PL1731605T3 (pl) | 2004-03-31 | 2010-08-31 | Int Inst Cancer Immunology Inc | Nowotworowe peptydy antygenowe pochodzące z WT1 |
DE102004049223A1 (de) | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
EP1782826A1 (fr) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS, c-diGMP et leurs conjugués utilisés comme adjuvants et leur emploi dans des compositions pharmaceutiques |
CA2631292C (fr) | 2005-11-30 | 2014-05-06 | International Institute Of Cancer Immunology, Inc. | Peptides antigenes de cancer wt1 derives et leur utilisation |
EP1962901A2 (fr) | 2005-12-01 | 2008-09-03 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Compositions et methodes relatives au traitement du cancer et de maladies infectieuses |
SI1988163T1 (sl) | 2006-02-22 | 2012-09-28 | Int Inst Cancer Immunology Inc | HLA-A*3303-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje |
US20080112974A1 (en) | 2006-09-08 | 2008-05-15 | Duotol Ab | Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens |
JP4925039B2 (ja) | 2006-09-21 | 2012-04-25 | 日東電工株式会社 | 糖材料の調製方法ならびに糖材料、糖材料を含むマイクロニードルおよびマイクロニードルをそなえてなる経皮製剤 |
US7935350B2 (en) * | 2006-12-14 | 2011-05-03 | Antigen Express, Inc. | Ii-key/Her-2/neu hybrid cancer vaccine |
NZ592510A (en) | 2006-12-28 | 2012-11-30 | Int Inst Cancer Immunology Inc | HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same |
EP2123296B1 (fr) * | 2007-01-31 | 2019-05-22 | Hisamitsu Pharmaceutical Co., Inc. | Adjuvant pour administration transdermique ou transmucosale et preparation pharmaceutique le contenant |
WO2009046738A1 (fr) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition pour traiter le cancer du poumon, notamment les cancers du poumon non à petites cellules (nsclc) |
US8557779B2 (en) * | 2007-12-05 | 2013-10-15 | International Institute Of Cancer Immunology, Inc. | Cancer vaccine composition |
HUE024541T2 (hu) * | 2008-05-14 | 2016-01-28 | Immatics Biotechnologies Gmbh | Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek |
US20110318380A1 (en) | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
AR076349A1 (es) * | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
CA2777400C (fr) | 2009-10-12 | 2018-11-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Granulysine dans l'immunotherapie |
GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
RU2697443C2 (ru) | 2013-02-05 | 2019-08-14 | Нитто Денко Корпорейшн | Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения |
CA2840997A1 (fr) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Composition de vaccin pour administration transdermique |
JP6512568B2 (ja) | 2013-02-05 | 2019-05-15 | 日東電工株式会社 | 経皮投与用wt1ペプチド癌ワクチン組成物 |
US20140220058A1 (en) | 2013-02-05 | 2014-08-07 | Nitto Denko Corporation | Vaccine composition for transdermal or mucosal administration |
KR20140100422A (ko) | 2013-02-05 | 2014-08-14 | 닛토덴코 가부시키가이샤 | 백신 조성물 |
-
2014
- 2014-01-29 JP JP2014014802A patent/JP6512568B2/ja not_active Expired - Fee Related
- 2014-01-29 EP EP14000324.5A patent/EP2762159A1/fr not_active Withdrawn
- 2014-01-29 IN IN391CH2014 patent/IN2014CH00391A/en unknown
- 2014-01-29 CN CN201410043149.8A patent/CN103961307B/zh not_active Expired - Fee Related
- 2014-01-29 RU RU2014102936A patent/RU2687144C2/ru not_active IP Right Cessation
- 2014-01-29 CA CA2841016A patent/CA2841016A1/fr not_active Abandoned
- 2014-01-29 KR KR1020140011634A patent/KR20140100419A/ko not_active Application Discontinuation
- 2014-01-29 US US14/166,932 patent/US10449144B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN103961307B (zh) | 2019-11-29 |
CN103961307A (zh) | 2014-08-06 |
JP6512568B2 (ja) | 2019-05-15 |
RU2014102936A (ru) | 2015-08-10 |
RU2687144C2 (ru) | 2019-05-07 |
JP2014169277A (ja) | 2014-09-18 |
US10449144B2 (en) | 2019-10-22 |
CA2841016A1 (fr) | 2014-08-05 |
US20140220055A1 (en) | 2014-08-07 |
KR20140100419A (ko) | 2014-08-14 |
EP2762159A1 (fr) | 2014-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CH00391A (fr) | ||
CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
MX2022004374A (es) | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer. | |
CY1120862T1 (el) | Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων | |
MX2023000320A (es) | Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion. | |
MX2016007063A (es) | Peptidos terapeuticos. | |
MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
MD4733C1 (ro) | Anticorpi anti-TIGIT | |
IN2014CH00393A (fr) | ||
MX2016017311A (es) | Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas. | |
IN2014CH00396A (fr) | ||
MX2015010880A (es) | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. | |
IN2014CH00395A (fr) | ||
MX2015010312A (es) | Metodos para tratamiento del melanoma. | |
MX2015016627A (es) | Vacuna para la malaria. | |
SG10201903119QA (en) | Polypeptide vaccine | |
MX2017004897A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
SG10201808746QA (en) | Methods for enhancing the efficacy of a tumor-directed immune response | |
MX2016014414A (es) | Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. | |
MX2017007595A (es) | Inmunoterapia para enfermedad angiogenica. | |
MX2016002937A (es) | Vacuna oncologica. | |
MY191539A (en) | Streptococcal vaccine | |
MX2016011295A (es) | Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2. | |
MX2018005544A (es) | Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer. |